Trial ID or NCT#
NCT00888927
Status
Purpose
This study will determine the maximum dose of KW-0761 administered intravenously that can be given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma(CTCL)and will see if it is effective in treating the disease.
Official Title
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects With Previously Treated Peripheral T-Cell Lymphoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Sunil Arani Reddy
Medical oncologist,
Cutaneous oncology specialist
Clinical Assistant Professor, Medicine - Oncology
Ranjana Advani
Lymphoma specialist,
Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
Contact us to find out if this trial is right for you.
CONTACT
Cancer Clinical Trials Office
(650) 498-7061
View on ClinicalTrials.gov